Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00862121 · ClinicalTrials.gov registry record · Phase 3
A Study With Pentasa in Patients With Active Crohn's Disease
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT00862121 is a Phase 3 study that was terminated before completion, run by Ferring Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT00862121, a Phase 3 study, was terminated before completion, sponsored by Ferring Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose and a 4 g evening dose is efficacious in active mild to moderate CD.
Interventions
- DRUG Placebo
- DRUG Pentasa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00862121
The ClinicalTrials.gov registry entry for NCT00862121 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00862121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00862121 about?
NCT00862121 is a clinical study titled "A Study With Pentasa in Patients With Active Crohn's Disease". The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose and a 4 g evening dose is efficacious in active mild to moderate CD.
What is the current status of trial NCT00862121?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2009-04. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00862121?
The interventions under investigation include: Placebo (DRUG), Pentasa (DRUG).
Who is sponsoring clinical trial NCT00862121?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.